← Leaderboards
Bhami C Shenoy
Altus Pharmaceuticals, Inc.
$1,037,137
Attributed
$1,037,137
Total exposure
4
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$1,037,137 · 4
By mechanism
R44$750,330 · 1
R43$286,807 · 3
Top collaborators
No co-investigators on record.
Most similar at Altus Pharmaceuticals, Inc.
Same institution · by research overlap
- Alexey L Margolin$300,000
Others in their field
Top investigators on “Biotechnology”
- David Heimbrook · Leidos Biomedical Research, Inc.$140,255,767
- Larry Arthur$82,860,406
- Jaap Goudsmit · Beth Israel Deaconess Medical Center$53,211,858
- Alfred G Gilman · University Of Texas Sw Med Ctr/Dallas$51,699,453
- Richard A Gibbs · Baylor College Of Medicine$51,685,612
- Garret A Fitzgerald · University Of Pennsylvania$50,415,853
Research focus
BiotechnologyCrystallizationDrug Delivery SystemsCrosslinkDrug Design /Synthesis /ProductionEnzyme ActivityEndopeptidasesEnzyme TherapyAcidity /AlkalinityChemical StabilityLipaseAmylasesAnalgesicsBiotherapeutic AgentDogsDosage FormsMalabsorptionPainPancreatitisSteatorrheaBiomedical EquipmentBiofilmBioassayGel Filtration Chromatography
Grant awards (5)
NOVEL PROTEASE FORMULATION BASED ON CROSSLINKED CRYSTALS$300,925
R44 · FY2004 · DK
NOVEL PROTEASE FORMULATION BASED ON CROSSLINKED CRYSTALS$449,405
R44 · FY2003 · DK
PREVENTION OF BIOFILMS IN MEDICAL DEVICES$100,000
R43 · FY2003 · AI
PROTEASE FORMULATION BASED ON CROSSLINKED ENZYME CRYSTAL$100,083
R43 · FY2001 · DK
NOVEL ENZYME FORMULATION FOR TREATMENT OF HYPEROXALURIA$86,724
R43 · FY2001 · DK